non-small cell lung cancer
Conditions
Interventions
oxitinib:None
Sponsors
Cancer Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) =18 years old male or female 2) Stage IV metastatic or recurrent non-squamous NSCLC that is newly diagnosed, histologically proven and not suitable for radical surgery or radiotherapy (AJCC V8); 3) Without prior systemic antitumor therapy including EGFR-TKI or immunotherapy; 4) EGFR positive in blood or tissue tested in local laboratory; 5) Sufficient blood samples can be provided for molecular detection; 6) Signed informed consent forms are available.
Exclusion criteria
Exclusion criteria: 1) Patients were unable to collect plasma samples at baseline; 2) The EGFR mutant status of the patient's blood specimen at baseline has not been verified by the central laboratory; 3) The patient refused subsequent treatment with oxitinib; 4)The investigator determines that may affect the conduct of the clinical study and the judgement of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data of plasma ctDNA EGFR mutation status and mutation type at baseline and ctDNA EGFR clearance 3 weeks after treatment were obtained by SuperARMS-PCR testing.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlation between EGFR-sensitive mutation clearance and PFS was monitored by SuperARMS-PCR testing.; | — |
Countries
China
Contacts
Public ContactWang Jie
Cancer Hospital Chinese Academy of Medical Sciences
Outcome results
None listed